MilliporeSigma
  • Home
  • Search Results
  • Capturing and identification of differentially expressed fucome by a gel free and label free approach.

Capturing and identification of differentially expressed fucome by a gel free and label free approach.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (2015-03-31)
Chanida Puangpila, Ziad El Rassi
ABSTRACT

This research reports a proof-of-concept that describes an instrumental approach that is gel free and label free at both the separation and mass spectrometry ends for the capturing and identification of differentially expressed proteins (DEPs) in diseases, e.g., cancers. The research consists of subjecting/processing equalized and non-equalized (i.e., untreated) disease-free and hepatocellular carcinoma (HCC) human sera via a multicolumn platform for capturing/fractionating human serum fucome. The equalization was performed via the combinatorial peptide ligand library (CPLL) beads technology that ensured narrowing the protein concentration range, thus allowing the detection of low abundance proteins. The equalized and non-equalized disease-free and HCC sera were first fractionated online onto two lectin columns specific to fucose, namely Aleuria aurantia lectin (AAL) and Lotus tetragonolobus agglutinin (LTA) followed by the online fractionation of the lectin captured fucome by reversed phase chromatography. The online desalted fractions were first subjected to trypsinolysis and then to liquid chromatography-mass spectrometry (LC-MS/MS) analysis. In comparison with untreated serum, the CPLL treated serum is superior in terms of the total number of identified DEPs, which reflected an increased number of DEPs in a wide abundance range. The DEPs in HCC serum were found to be 70 and 40 in both LTA and AAL fractions for the serum treated by CPLL and untreated serum, respectively. In addition, the platform combined with the CPLL treatment was accomplished with virtually no sample loss and dilution as well as with no experimental biases and sample labeling when comparing the diseased-free and cancer sera using LC-MS/MS.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Tromethamine, meets USP testing specifications
Sigma-Aldrich
Sigma 7-9®, ≥99% (titration), crystalline
Supelco
1-Dodecanol, Selectophore, ≥98.0%
Sigma-Aldrich
Lauryl alcohol, ≥98%, FG
Supelco
Trifluoroacetic acid, analytical standard
Sigma-Aldrich
2,2′-Azobis(2-methylpropionitrile), 98%
Sigma-Aldrich
Trizma® base, puriss. p.a., ≥99.7% (T)
Sigma-Aldrich
Trizma® base, ≥99.0% (T)
Sigma-Aldrich
Sodium (meta)periodate, BioUltra, ≥99.5% (RT)
Supelco
Trizma® base, certified reference material for titrimetry, certified by BAM, ≥99.5%
Sigma-Aldrich
Tris(hydroxymethyl)aminomethane, ACS reagent, ≥99.8%
Sigma-Aldrich
Sodium cyanoborohydride solution, 1.0 M in THF
Sigma-Aldrich
Sodium cyanoborohydride, reagent grade, 95%
Sigma-Aldrich
Sodium cyanoborohydride solution, 5.0 M in 1 M NaOH
Sigma-Aldrich
Trizma® base, BioUltra, for molecular biology, ≥99.8% (T)
Sigma-Aldrich
Trizma® base, ≥99.9% (titration), crystalline
Sigma-Aldrich
Trizma® base, BioXtra, pH 10.5-12.0 (1 M in H2O), ≥99.9% (titration)
Sigma-Aldrich
L-(−)-Fucose, ≥99%
Sigma-Aldrich
Trizma® base, BioPerformance Certified, meets EP, USP testing specifications, suitable for cell culture, ≥99.9% (titration)
Sigma-Aldrich
Trizma® base, Primary Standard and Buffer, ≥99.9% (titration), crystalline